|
🐢
|
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
12 auth.
B. Ramsey,
M. Pepe,
Joanne M. Quan,
K. Otto,
A. Montgomery,
J. Williams‐Warren,
...
Michael Vasiljev-K,
D. Borowitz,
C. M. Bowman,
B. Marshall,
S. Marshall,
Arnold L. Smith
|
10 |
1999 |
10
🐢
|
|
🐜
|
Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.
11 auth.
J. Burns,
R. Gibson,
S. Mcnamara,
Darlene L. Yim,
J. Emerson,
M. Rosenfeld,
...
P. Hiatt,
K. McCoy,
R. Castile,
Arnold L. Smith,
B. Ramsey
|
9 |
2001 |
9
🐜
|
|
🐢
|
Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
12 auth.
B. Ramsey,
H. Dorkin,
J. Eisenberg,
R. Gibson,
I. Harwood,
R. Kravitz,
...
D. Schidlow,
R. Wilmott,
S. Astley,
M. McBurnie,
K. Wentz,
Arnold L. Smith
|
8 |
1993 |
8
🐢
|
|
🐜
|
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis *
13 auth.
M. Rosenfeld,
R. Gibson,
S. Mcnamara,
J. Emerson,
J. Burns,
R. Castile,
P. Hiatt,
K. McCoy,
Christopher B Wilson,
A. Inglis,
...
Arnold L. Smith,
T. Martin,
B. Ramsey
|
8 |
2001 |
8
🐜
|
|
🐜
|
Defining a pulmonary exacerbation in cystic fibrosis.
7 auth.
M. Rosenfeld,
J. Emerson,
J. Williams‐Warren,
M. Pepe,
Arnold L. Smith,
A. Montgomery,
...
B. Ramsey
|
8 |
2001 |
8
🐜
|
|
🐢
|
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
10 auth.
J. Burns,
Jill M. Van Dalfsen,
R. Shawar,
K. Otto,
R. Garber,
Joanne M. Quan,
...
A. Montgomery,
G. Albers,
B. Ramsey,
Arnold L. Smith
|
8 |
1999 |
8
🐢
|
|
🐢
|
Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
16 auth.
B. Ramsey,
S. Astley,
M. Aitken,
W. Burke,
A. Colin,
H. Dorkin,
J. Eisenberg,
R. Gibson,
I. Harwood,
D. Schidlow,
...
R. Wilmott,
M. Wohl,
L. Meyerson,
S. Shak,
H. Fuchs,
Arnold L. Smith
|
7 |
1993 |
7
🐢
|
|
🐢
|
Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.
M. Aitken,
W. Burke,
Gwendolyn McDonald,
S. Shak,
A. Montgomery,
Arnold L. Smith
|
7 |
1992 |
7
🐢
|
|
🦁
|
Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
8 auth.
Arnold L. Smith,
B. Ramsey,
Donna L. Hedges,
Barbara Hack,
J. Williams‐Warren,
A. Weber,
...
Edmond J. Gore,
G. Redding
|
7 |
1989 |
7
🦁
|
|
🐜
|
Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission
9 auth.
U. Schaad,
M. Salam,
Y. Aujard,
R. Dagan,
S. Green,
H. Peltola,
...
T. Rubio,
Arnold L. Smith,
D. Adam
|
7 |
1995 |
7
🐜
|
|
🦁
|
Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis.
17 auth.
Arnold L. Smith,
Gregory Redding,
C. Doershuk,
D. Goldmann,
Edmond J. Gore,
B. Hilman,
M. Marks,
R. Moss,
B. Ramsey,
T. Roblo,
...
R. Schwartz,
M. Thomassen,
J. Williams‐Warren,
A. Weber,
R. Wilmott,
H. Wilson,
R. Yogev
|
7 |
1988 |
7
🦁
|
|
🐬
|
The effect of respiratory viral infections on patients with cystic fibrosis.
B. Ramsey,
Edmond J. Gore,
Arnold L. Smith,
M. Cooney,
G. Redding,
H. Foy
|
6 |
1989 |
6
🐬
|
